T-cell therapy after hematopoietic stem cell transplantation
- 1 November 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 14 (6) , 616-624
- https://doi.org/10.1097/moh.0b013e3282ef615a
Abstract
The separation of graft versus host disease from graft versus leukaemia reactivity and the reconstitution of immunity to infectious agents are the main goals of T-cell therapy after allogeneic hematopoietic stem cell transplantation. We describe how an improved understanding of T-cell mediated graft versus leukemia and of antiviral responses is providing effective approaches to T-cell immunotherapy. Over the past several years, researchers have developed strategies to eliminate alloreactive T cells from the graft, to expand naturally occurring regulatory T cells, and to select and expand antigen-specific T cells specific for tumor-associated or viral antigens. Incorporation of suicide genes allows the selective destruction of allodepleted or antigen-selected cells after infusion, further increasing the safety and potential applicability of these approaches. In this review we describe current strategies for adoptive T-cell immunotherapy after hematopoietic stem cell transplantation.Keywords
This publication has 54 references indexed in Scilit:
- Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantationBlood, 2006
- Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytesBone Marrow Transplantation, 2005
- Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective studyBone Marrow Transplantation, 2005
- Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationThe Lancet, 2005
- Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease responseBone Marrow Transplantation, 2004
- CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot studyBone Marrow Transplantation, 2004
- Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesBlood, 2004
- Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 studyThe Lancet, 2002
- Treatment of Epstein-Barr virus-associated malignancies with specific T cellsPublished by Elsevier ,2002
- Treatment of relapsed Hodgkin’s disease using EBV-specific cytotoxic T cellsAnnals of Oncology, 1998